NATICK, Mass., Dec. 7, 2010 /PRNewswire/ — Boston Scientific
Corporation (NYSE:
BSX) today welcomed the publication of an analysis from its
ALTITUDE® Clinical Science program in the current issue of
Circulation that showed patients followed by the
LATITUDE® Patient Management system experienced a 50 percent
relative reduction in the risk of death compared to patients
followed in-clinic only. The analysis also showed that heart
failure patients who transmitted weight and blood pressure data via
the LATITUDE system experienced an additional 10 percent reduction
in the risk of death compared to other CRT-D patients followed by
the LATITUDE system.
Boston Scientific has enrolled more than 180,000 patients on the
LATITUDE system since its introduction in 2006. The LATITUDE
system enables physicians to conduct remote follow-up of
implantable cardiac device patients to monitor specific device
information and heart health status. The system can also
detect clinical events between scheduled in-clinic visits and send
relevant data directly to physicians.
The ALTITUDE program enhances physician understanding of device
therapy, outcomes and disease progression in a real-world setting
for device patients followed by the LATITUDE system.
“Patients remotely monitored by physicians may fare better due
to earlier notification of events, resulting in diagnosis or
therapy that can reduce subsequent risk,” said Leslie Saxon, M.D.,
F.A.C.C., Chief, Cardiovascular Medicine at the Cardiovascular and
Thoracic Institute, University of Southern California, and
chairperson of the ALTITUDE physician panel. “Remote
follow-up may also encourage patients to be more aware of their
health status.”
Boston Scientific is a worldwide developer, manufacturer and
marketer of medical devices whose products are used in a broad
range of inter
‘/>”/>
SOURCE